The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. His work has demonstrated the importance of analytical methodologies for tumor markers, endocrine or clinical chemistry assays to determine the clinical outcomes of a patient's disease process. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, breast and ovarian cancer biomarkers. He has edited and written five books on immunoassay, immunoassay automation, diagnostic endocrinology, and tumor markers. Dr. Chan has published over 200 articles including the tumor markers chapters in the Tietz Textbook of Clinical Chemistry and in Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, which he also co-edited.
Dr. Chan is actively involved in the Human Proteome Organization (HUPO) and its Plasma Proteome Initiative. He serves as chairman of a HUPO committee responsible for the development of reference specimens for a global comprehensive study of the human proteome.